Back to Directory
Hijack Bio
Greater London
Founded 2024
Engineered probiotic bacteria producing peptide therapeutics inside the body
Hijack Bio develops engineered probiotic bacteria designed to produce and release peptide therapeutics inside the body.
The synthetic biology approach aims to reduce reliance on conventional external manufacturing and cold-chain distribution while enabling oral delivery of peptide drugs.
Potential applications include treatments based on insulin and GLP-1 agonists, although the platform is being developed rather than offered as an approved alternative to existing injectable medicines.